Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders (original) (raw)

• Berdasco, M. & Esteller, M. Genetic syndromes caused by mutations in epigenetic genes. Hum. Genet. 132, 359–383 (2013).
  CAS PubMed Google Scholar
• Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome — biological and translational implications. Nature Rev. Cancer 11, 726–734 (2011).
  CAS Google Scholar
• Berger, S. L. The complex language of chromatin regulation during transcription. Nature 447, 407–412 (2007).
  CAS PubMed Google Scholar
• Kouzarides, T. Chromatin modifications and their function. Cell 128, 693–705 (2007).
  CAS PubMed Google Scholar
• Dawson, M. A. & Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 150, 12–27 (2012).
  CAS PubMed Google Scholar
• Dawson, M. A., Kouzarides, T. & Huntly, B. J. Targeting epigenetic readers in cancer. N. Engl. J. Med. 367, 647–657 (2012). References 5 and 6 are excellent review articles providing a contemporary view of the links between cancer genetics and epigenetics.
  CAS PubMed Google Scholar
• Kaminskas, E. et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res. 11, 3604–3608 (2005).
  CAS PubMed Google Scholar
• Kaminskas, E., Farrell, A. T., Wang, Y. C., Sridhara, R. & Pazdur, R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10, 176–182 (2005).
  CAS PubMed Google Scholar
• Daigle, S. R. et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122, 1017–1025 (2013).
  CAS PubMed PubMed Central Google Scholar
• Yu, W. et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nature Commun. 3, 1288 (2012).
  Google Scholar
• McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108–112 (2012).
  CAS PubMed Google Scholar
• Knutson, S. K. et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nature Chem. Biol. 8, 890–896 (2012).
  CAS Google Scholar
• Bonham, K. et al. Effects of a novel arginine methyltransferase inhibitor on T-helper cell cytokine production. FEBS J. 277, 2096–2108 (2010).
  CAS PubMed PubMed Central Google Scholar
• Kleinschmidt, M. A., de Graaf, P., van Teeffelen, H. A. & Timmers, H. T. Cell cycle regulation by the PRMT6 arginine methyltransferase through repression of cyclin-dependent kinase inhibitors. PLoS ONE 7, e41446 (2012).
  CAS PubMed PubMed Central Google Scholar
• West, A. C. & Johnstone, R. W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30–39 (2014).
  CAS PubMed PubMed Central Google Scholar
• Schenk, T. et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-_trans_-retinoic acid differentiation pathway in acute myeloid leukemia. Nature Med. 18, 605–611 (2012).
  CAS PubMed Google Scholar
• Willmann, D. et al. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int. J. Cancer 131, 2704–2709 (2012).
  CAS PubMed Google Scholar
• Shi, L., Cui, S., Engel, J. D. & Tanabe, O. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. Nature Med. 19, 291–294 (2013).
  CAS PubMed Google Scholar
• Frieling, H. & Bleich, S. Tranylcypromine: new perspectives on an “old” drug. Eur. Arch. Psychiatry Clin. Neurosci. 256, 268–273 (2006).
  PubMed Google Scholar
• Tedeschini, E. et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J. Clin. Psychiatry 72, 1660–1668 (2011).
  CAS PubMed Google Scholar
• Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010).
  CAS PubMed PubMed Central Google Scholar
• Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119–1123 (2010).
  CAS PubMed PubMed Central Google Scholar
• Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Mertz, J. A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. USA 108, 16669–16674 (2011).
  CAS PubMed PubMed Central Google Scholar
• Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529–533 (2011).
  CAS PubMed PubMed Central Google Scholar
• Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524–528 (2011).
  CAS PubMed PubMed Central Google Scholar
• Bandukwala, H. S. et al. Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. Proc. Natl Acad. Sci. USA 109, 14532–14537 (2012).
  CAS PubMed PubMed Central Google Scholar
• Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834–840 (2009). This is an important demonstration of non-histone substrates of HDACs and the biological effects of protein acetylation.
  CAS PubMed Google Scholar
• Jaenisch, R. & Bird, A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nature Genet. 33, S245–S454 (2003). References 23–29 demonstrate the antitumour activities of novel bromodomain inhibitors.
  Google Scholar
• Rafehi, H. et al. Vascular histone deacetylation by pharmacological HDAC inhibition. Genome Res. http://dx.doi.org/10.1101/gr.168781.113 (2014).
• Dudakovic, A. et al. Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation. J. Biol. Chem. 288, 28783–28791 (2013).
  CAS PubMed PubMed Central Google Scholar
• Peart, M. J. et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 3697–3702 (2005).
  CAS PubMed PubMed Central Google Scholar
• Gray, S. G., Qian, C. N., Furge, K., Guo, X. & Teh, B. T. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int. J. Oncol. 24, 773–795 (2004).
  CAS PubMed Google Scholar
• Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nature Biotech. 29, 255–265 (2011). This is a demonstration of the functional role of HDACs in multiprotein complexes and the use of chromoproteomics to demonstrate the specificity of HDAC inhibitors in physiological circumstances.
  CAS Google Scholar
• Delcuve, G. P., Khan, D. H. & Davie, J. R. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin. Epigenet. 4, 5 (2012).
  CAS Google Scholar
• Leder, A. & Leder, P. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell 5, 319–322 (1975).
  CAS PubMed Google Scholar
• Riggs, M. G., Whittaker, R. G., Neumann, J. R. & Ingram, V. M. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268, 462–464 (1977).
  CAS PubMed Google Scholar
• Licht, J. D. AML1 and the AML1–ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 20, 5660–5679 (2001).
  CAS PubMed Google Scholar
• Liu, Y. et al. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell 9, 249–260 (2006).
  PubMed Google Scholar
• Peterson, L. F. & Zhang, D. E. The 8;21 translocation in leukemogenesis. Oncogene 23, 4255–4262 (2004).
  CAS PubMed Google Scholar
• Minucci, S. & Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Rev. Cancer 6, 38–51 (2006).
  CAS Google Scholar
• Di Croce, L. et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079–1082 (2002).
  CAS PubMed Google Scholar
• Rego, E. M. et al. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins. Proc. Natl Acad. Sci. USA 97, 10173–10178 (2000).
  CAS PubMed PubMed Central Google Scholar
• Licht, J. D. et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85, 1083–1094 (1995).
  CAS PubMed Google Scholar
• Halkidou, K. et al. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59, 177–189 (2004).
  CAS PubMed Google Scholar
• Zimmermann, S. et al. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res. 67, 9047–9054 (2007).
  CAS PubMed Google Scholar
• Bhaskara, S. et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 18, 436–447 (2010). This study indicates a tumour-suppressive role for HDAC3.
  CAS PubMed PubMed Central Google Scholar
• Dovey, O. M. et al. Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice. Blood 121, 1335–1344 (2013).
  CAS PubMed Google Scholar
• Heideman, M. R. et al. Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood 121, 2038–2050 (2013).
  CAS PubMed PubMed Central Google Scholar
• Santoro, F. et al. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 121, 3459–3468 (2013). References 48–50 provide experimental evidence supporting the tumour-suppressive functions of HDAC1 and HDAC2.
  CAS PubMed Google Scholar
• Guan, J. S. et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459, 55–60 (2009).
  CAS PubMed PubMed Central Google Scholar
• Graff, J. et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483, 222–226 (2012).
  PubMed PubMed Central Google Scholar
• Montgomery, R. L., Hsieh, J., Barbosa, A. C., Richardson, J. A. & Olson, E. N. Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. Proc. Natl Acad. Sci. USA 106, 7876–7881 (2009).
  CAS PubMed PubMed Central Google Scholar
• Akhtar, M. W. et al. Histone deacetylases 1 and 2 form a developmental switch that controls excitatory synapse maturation and function. J. Neurosci. 29, 8288–8297 (2009).
  CAS PubMed PubMed Central Google Scholar
• Majdzadeh, N., Morrison, B. E. & D'Mello, S. R. Class IIA HDACs in the regulation of neurodegeneration. Front. Biosci. 13, 1072–1082 (2008).
  CAS PubMed PubMed Central Google Scholar
• Majdzadeh, N. et al. HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev. Neurobiol. 68, 1076–1092 (2008).
  CAS PubMed PubMed Central Google Scholar
• Kim, M. S. et al. An essential role for histone deacetylase 4 in synaptic plasticity and memory formation. J. Neurosci. 32, 10879–10886 (2012).
  CAS PubMed PubMed Central Google Scholar
• Williams, S. R. et al. Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems. Am. J. Hum. Genet. 87, 219–228 (2010).
  CAS PubMed PubMed Central Google Scholar
• Fukada, M. et al. Loss of deacetylation activity of Hdac6 affects emotional behavior in mice. PLoS ONE 7, e30924 (2012).
  CAS PubMed PubMed Central Google Scholar
• Lee, V. M., Goedert, M. & Trojanowski, J. Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121–1159 (2001).
  CAS PubMed Google Scholar
• Min, S. W. et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953–966 (2010).
  CAS PubMed PubMed Central Google Scholar
• Cohen, T. J. et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nature Commun. 2, 252 (2011).
  Google Scholar
• Irwin, D. J. et al. Acetylated tau neuropathology in sporadic and hereditary tauopathies. Am. J. Pathol. 183, 344–351 (2013).
  CAS PubMed PubMed Central Google Scholar
• Selenica, M. L. et al. Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimers Res. Ther. 6, 12 (2014).
  PubMed PubMed Central Google Scholar
• Cook, C. et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum. Mol. Genet. 23, 104–116 (2014).
  CAS PubMed Google Scholar
• Simoes-Pires, C. et al. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol. Neurodegener. 8, 7 (2013).
  CAS PubMed PubMed Central Google Scholar
• Jeong, H. et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 137, 60–72 (2009). This is a landmark demonstration of the role of acetylated HTT in Huntington's disease.
  CAS PubMed PubMed Central Google Scholar
• Govindarajan, N. et al. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol. Med. 5, 52–63 (2013).
  CAS PubMed Google Scholar
• Dompierre, J. P. et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 27, 3571–3583 (2007).
  CAS PubMed PubMed Central Google Scholar
• Bobrowska, A., Paganetti, P., Matthias, P. & Bates, G. P. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. PLoS ONE 6, e20696 (2011).
  CAS PubMed PubMed Central Google Scholar
• Pandey, U. B. et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447, 859–863 (2007).
  CAS PubMed Google Scholar
• Brady, R. O., Kanfer, J. N., Bradley, R. M. & Shapiro, D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J. Clin. Invest. 45, 1112–1115 (1966).
  CAS PubMed PubMed Central Google Scholar
• Lu, J. et al. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc. Natl Acad. Sci. USA 108, 21200–21205 (2011).
  CAS PubMed PubMed Central Google Scholar
• Kovacs, J. J. et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18, 601–607 (2005).
  CAS PubMed Google Scholar
• Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P. & Sweet, M. J. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 32, 335–343 (2011).
  CAS PubMed Google Scholar
• Hancock, W. W., Akimova, T., Beier, U. H., Liu, Y. & Wang, L. HDAC inhibitor therapy in autoimmunity and transplantation. Ann. Rheum. Dis. 71 (Suppl. 2), 46–54 (2012).
  Google Scholar
• Sweet, M. J., Shakespear, M. R., Kamal, N. A. & Fairlie, D. P. HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation. Immunol. Cell Biol. 90, 14–22 (2012).
  CAS PubMed Google Scholar
• Xu, M., Nie, L., Kim, S. H. & Sun, X. H. STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPβ. EMBO J. 22, 893–904 (2003).
  CAS PubMed PubMed Central Google Scholar
• Kramer, O. H. et al. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev. 23, 223–235 (2009).
  PubMed PubMed Central Google Scholar
• Klampfer, L., Huang, J., Swaby, L. A. & Augenlicht, L. Requirement of histone deacetylase activity for signaling by STAT1. J. Biol. Chem. 279, 30358–30368 (2004).
  CAS PubMed Google Scholar
• Chang, H. M. et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl Acad. Sci. USA 101, 9578–9583 (2004).
  CAS PubMed PubMed Central Google Scholar
• Nusinzon, I. & Horvath, C. M. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl Acad. Sci. USA 100, 14742–14747 (2003).
  CAS PubMed PubMed Central Google Scholar
• Lobera, M. et al. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nature Chem. Biol. 9, 319–325 (2013).
  CAS Google Scholar
• Shakespear, M. R. et al. Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophages. J. Biol. Chem. 288, 25362–25374 (2013).
  CAS PubMed PubMed Central Google Scholar
• Barneda-Zahonero, B. et al. HDAC7 is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages. PLoS Genet. 9, e1003503 (2013).
  CAS PubMed PubMed Central Google Scholar
• Navarro, M. N., Goebel, J., Feijoo-Carnero, C., Morrice, N. & Cantrell, D. A. Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes. Nature Immunol. 12, 352–361 (2011).
  CAS Google Scholar
• de Zoeten, E. F., Wang, L., Sai, H., Dillmann, W. H. & Hancock, W. W. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 138, 583–594 (2010).
  CAS PubMed Google Scholar
• Tao, R. et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nature Med. 13, 1299–1307 (2007). This is an important study demonstrating the role of HDACs in regulating immune responses.
  CAS PubMed Google Scholar
• de Zoeten, E. F. et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3+ T-regulatory cells. Mol. Cell. Biol. 31, 2066–2078 (2011).
  CAS PubMed PubMed Central Google Scholar
• Serrador, J. M. et al. HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. Immunity 20, 417–428 (2004).
  CAS PubMed Google Scholar
• Cabrero, J. R. et al. Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol. Biol. Cell 17, 3435–3445 (2006).
  CAS PubMed PubMed Central Google Scholar
• Yamaguchi, T. et al. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev. 24, 455–469 (2010).
  CAS PubMed PubMed Central Google Scholar
• Grausenburger, R. et al. Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J. Immunol. 185, 3489–3497 (2010).
  CAS PubMed Google Scholar
• Villagra, A. et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nature Immunol. 10, 92–100 (2009).
  CAS Google Scholar
• Margolis, D. M. Histone deacetylase inhibitors and HIV latency. Curr. Opin. HIV AIDS 6, 25–29 (2011).
  PubMed PubMed Central Google Scholar
• Bullen, C. K., Laird, G. M., Durand, C. M., Siliciano, J. D. & Siliciano, R. F. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nature Med. 20, 425–429 (2014).
  CAS PubMed Google Scholar
• Zhou, G., Du, T. & Roizman, B. The role of the CoREST/REST repressor complex in herpes simplex virus 1 productive infection and in latency. Viruses 5, 1208–1218 (2013).
  CAS PubMed PubMed Central Google Scholar
• Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Rev. Drug Discov. 1, 287–299 (2002).
  CAS Google Scholar
• Fischle, W. et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9, 45–57 (2002).
  CAS PubMed Google Scholar
• Backs, J., Backs, T., Bezprozvannaya, S., McKinsey, T. A. & Olson, E. N. Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4. Mol. Cell. Biol. 28, 3437–3445 (2008).
  CAS PubMed PubMed Central Google Scholar
• Kong, H. S. et al. Preclinical studies of YK-4-272, an inhibitor of class II histone deacetylases by disruption of nucleocytoplasmic shuttling. Pharm. Res. 29, 3373–3383 (2012).
  CAS PubMed PubMed Central Google Scholar
• Lahm, A. et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl Acad. Sci. USA 104, 17335–17340 (2007).
  CAS PubMed PubMed Central Google Scholar
• Herman, D. et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nature Chem. Biol. 2, 551–558 (2006).
  CAS Google Scholar
• Rai, M. et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3, e1958 (2008).
  PubMed PubMed Central Google Scholar
• Sandi, C. et al. Prolonged treatment with pimelic _O_-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol. Dis. 42, 496–505 (2011).
  CAS PubMed PubMed Central Google Scholar
• Soragni, E. et al. Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia. J. Child Neurol. 27, 1164–1173 (2012).
  PubMed PubMed Central Google Scholar
• Wells, C. E. et al. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS ONE 8, e68915 (2013).
  CAS PubMed PubMed Central Google Scholar
• Minami, J. et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia 28, 680–689 (2013).
  PubMed PubMed Central Google Scholar
• Santo, L. et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119, 2579–2589 (2012).
  CAS PubMed PubMed Central Google Scholar
• McConkey, D. J., White, M. & Yan, W. HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer. Adv. Cancer Res. 116, 131–163 (2012).
  CAS PubMed Google Scholar
• Newbold, A. et al. Molecular and biological analysis of histone deacetylase inhibitors with diverse specificities. Mol. Cancer Ther. 12, 2709–2721 (2013).
  CAS PubMed Google Scholar
• Schroeder, F. A. et al. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS ONE 8, e71323 (2013).
  CAS PubMed PubMed Central Google Scholar
• Ai, T., Cui, H. & Chen, L. Multi-targeted histone deacetylase inhibitors in cancer therapy. Curr. Med. Chem. 19, 475–487 (2012).
  CAS PubMed Google Scholar
• Qian, C. et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin. Cancer Res. 18, 4104–4113 (2012).
  CAS PubMed Google Scholar
• Lai, C. J. et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 70, 3647–3656 (2010).
  CAS PubMed Google Scholar
• Wang, J. et al. Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. Mol. Cancer Ther. 12, 925–936 (2013).
  CAS PubMed Google Scholar
• Needham, L. A. et al. Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs. J. Pharmacol. Exp. Ther. 339, 132–142 (2011).
  CAS PubMed Google Scholar
• Ossenkoppele, G. J. et al. A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies. Br. J. Haematol. 162, 191–201 (2013).
  CAS PubMed Google Scholar
• Guerrant, W., Patil, V., Canzoneri, J. C. & Oyelere, A. K. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J. Med. Chem. 55, 1465–1477 (2012).
  CAS PubMed PubMed Central Google Scholar
• Guerrant, W. et al. Dual-acting histone deacetylase-topoisomerase I inhibitors. Bioorg. Med. Chem. Lett. 23, 3283–3287 (2013).
  CAS PubMed PubMed Central Google Scholar
• Chen, G. L. et al. Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay. Bioorg. Med. Chem. Lett. 23, 3891–3895 (2013).
  CAS PubMed Google Scholar
• Gryder, B. E. et al. Histone deacetylase inhibitors equipped with estrogen receptor modulation activity. J. Med. Chem. 56, 5782–5796 (2013).
  CAS PubMed Google Scholar
• Chen, J. B. et al. Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment. J. Med. Chem. 56, 3645–3655 (2013).
  CAS PubMed Google Scholar
• Tavera-Mendoza, L. E. et al. Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist. Proc. Natl Acad. Sci. USA 105, 8250–8255 (2008).
  CAS PubMed PubMed Central Google Scholar
• Lamblin, M. et al. Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids. Bioorg. Med. Chem. 18, 4119–4137 (2010).
  CAS PubMed Google Scholar
• Ko, K. S., Steffey, M. E., Brandvold, K. R. & Soellner, M. B. Development of a chimeric c-Src kinase and HDAC inhibitor. ACS Med. Chem. Lett. 4, 779–783 (2013).
  CAS PubMed PubMed Central Google Scholar
• Patel, H. K. et al. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy. ChemMedChem 9, 602–613 (2013).
  PubMed PubMed Central Google Scholar
• Weinstein, I. B. Cancer. Addiction to oncogenes — the Achilles heal of cancer. Science 297, 63–64 (2002).
  CAS PubMed Google Scholar
• Bolden, J. E. et al. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis. 4, e519 (2013).
  CAS PubMed PubMed Central Google Scholar
• Insinga, A. et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Med. 11, 71–76 (2005).
  CAS PubMed Google Scholar
• Nebbioso, A. et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Med. 11, 77–84 (2005). References 130 and 131 demonstrate a role for the death receptor pathway in mediating apoptosis induced by HDAC inhibitors.
  CAS PubMed Google Scholar
• Ungerstedt, J. S. et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 673–678 (2005).
  CAS PubMed PubMed Central Google Scholar
• Fuino, L. et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2, 971–984 (2003).
  CAS PubMed Google Scholar
• Bali, P. et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729–26734 (2005).
  CAS PubMed Google Scholar
• Nimmanapalli, R. et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 63, 5126–5135 (2003).
  CAS PubMed Google Scholar
• Yu, W. et al. Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor. Leuk. Res. 35, 1212–1218 (2011).
  CAS PubMed Google Scholar
• Wang, Y. et al. FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochem. Biophys. Res. Commun. 356, 998–1003 (2007).
  CAS PubMed Google Scholar
• Nguyen, T. et al. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin. Cancer Res. 17, 3219–3232 (2011).
  CAS PubMed PubMed Central Google Scholar
• Jaboin, J. et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 62, 6108–6115 (2002).
  CAS PubMed Google Scholar
• Stumpel, D. J. et al. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia 26, 682–692 (2012).
  CAS PubMed Google Scholar
• Marshall, G. M. et al. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 29, 5957–5968 (2010).
  CAS PubMed Google Scholar
• Zhang, X. et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. Cancer Cell 22, 506–523 (2012).
  CAS PubMed PubMed Central Google Scholar
• Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nature Rev. Drug Discov. 5, 769–784 (2006).
  CAS Google Scholar
• Ellis, L. et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 114, 380–393 (2009).
  CAS PubMed PubMed Central Google Scholar
• Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72 (2013).
  CAS PubMed Google Scholar
• Setiadi, A. F. et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res. 68, 9601–9607 (2008).
  CAS PubMed Google Scholar
• Christiansen, A. J. et al. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc. Natl Acad. Sci. USA 108, 4141–4146 (2011).
  CAS PubMed PubMed Central Google Scholar
• West, A. C. et al. An intact immune system is required for the anti-cancer activities of histone deacetylase inhibitors. Cancer Res. 73, 7265–7276 (2013).
  CAS PubMed Google Scholar
• Schwartz, B. E. et al. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 71, 2686–2696 (2011).
  CAS PubMed PubMed Central Google Scholar
• Bots, M. et al. Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood 123, 1341–1352 (2014).
  CAS PubMed PubMed Central Google Scholar
• Duvic, M. et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109, 31–39 (2007).
  CAS PubMed PubMed Central Google Scholar
• VanderMolen, K. M., McCulloch, W., Pearce, C. J. & Oberlies, N. H. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J. Antibiot. 64, 525–531 (2011).
  CAS Google Scholar
• New, M., Olzscha, H. & La Thangue, N. B. HDAC inhibitor-based therapies: can we interpret the code? Mol. Oncol. 6, 637–656 (2012).
  CAS PubMed PubMed Central Google Scholar
• Nebbioso, A., Carafa, V., Benedetti, R. & Altucci, L. Trials with 'epigenetic' drugs: an update. Mol. Oncol. 6, 657–682 (2012).
  CAS PubMed PubMed Central Google Scholar
• Qiu, T. et al. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. Future Oncol. 9, 255–269 (2013).
  CAS PubMed Google Scholar
• Garcia-Manero, G. et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J. Clin. Oncol. 30, 2204–2210 (2012).
  CAS PubMed PubMed Central Google Scholar
• Bots, M. & Johnstone, R. W. Rational combinations using HDAC inhibitors. Clin. Cancer Res. 15, 3970–3977 (2009).
  CAS PubMed Google Scholar
• Thurn, K. T., Thomas, S., Moore, A. & Munster, P. N. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 7, 263–283 (2011).
  CAS PubMed Google Scholar
• Blum, W. et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J. Clin. Oncol. 25, 3884–3891 (2007).
  CAS PubMed Google Scholar
• Badros, A. et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin. Cancer Res. 15, 5250–5257 (2009).
  CAS PubMed PubMed Central Google Scholar
• Weber, D. M. et al. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 12, 319–324 (2012).
  CAS PubMed Google Scholar
• Millward, M. et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest. New Drugs 30, 2303–2317 (2012).
  CAS PubMed Google Scholar
• Dasmahapatra, G. et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 115, 4478–4487 (2010).
  CAS PubMed PubMed Central Google Scholar
• Dasmahapatra, G. et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol. Cancer Ther. 10, 1686–1697 (2011).
  CAS PubMed PubMed Central Google Scholar
• Munster, P. N. et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br. J. Cancer 104, 1828–1835 (2011).
  CAS PubMed PubMed Central Google Scholar
• Faller, D. V., Mentzer, S. J. & Perrine, S. P. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr. Opin. Oncol. 13, 360–367 (2001).
  CAS PubMed Google Scholar
• Perrine, S. P. et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109, 2571–2578 (2007).
  CAS PubMed PubMed Central Google Scholar
• Ghosh, S. K., Perrine, S. P., Williams, R. M. & Faller, D. V. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood 119, 1008–1017 (2012).
  CAS PubMed PubMed Central Google Scholar
• Johnstone, R. W., Frew, A. J. & Smyth, M. J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nature Rev. Cancer 8, 782–798 (2008).
  CAS Google Scholar
• Frew, A. J. et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc. Natl Acad. Sci. USA 105, 11317–11322 (2008).
  CAS PubMed PubMed Central Google Scholar
• Martin, B. P. et al. Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. Int. J. Cancer 128, 2735–2747 (2011).
  CAS PubMed Google Scholar
• Whitecross, K. F. et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 113, 1982–1991 (2009).
  CAS PubMed Google Scholar
• Chuang, D. M., Leng, Y., Marinova, Z., Kim, H. J. & Chiu, C. T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 32, 591–601 (2009).
  CAS PubMed PubMed Central Google Scholar
• Jia, H. et al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol. Dis. 46, 351–361 (2012).
  CAS PubMed PubMed Central Google Scholar
• Steffan, J. S. et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413, 739–743 (2001).
  CAS PubMed Google Scholar
• Kim, D. et al. Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron 60, 803–817 (2008).
  CAS PubMed PubMed Central Google Scholar
• Kozikowski, A. P. et al. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. J. Med. Chem. 50, 3054–3061 (2007).
  CAS PubMed Google Scholar
• Butler, K. V. et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 132, 10842–10846 (2010).
  CAS PubMed PubMed Central Google Scholar
• Zhang, L. et al. Tubastatin A/ACY-1215 improves cognition in alzheimer's disease transgenic mice. J. Alzheimers Dis. http://dx.doi.org/10.3233/JAD-140066 (2014).
• Zhang, L., Sheng, S. & Qin, C. The role of HDAC6 in Alzheimer's disease. J. Alzheimers Dis. 33, 283–295 (2013).
  PubMed Google Scholar
• Subramanian, S., Bates, S., Wright, J., Espinoza-Delgado, I. & Piekarz, R. Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 3, 2751–2767 (2010).
  CAS PubMed PubMed Central Google Scholar
• Seo, J., Howell, M. D., Singh, N. N. & Singh, R. N. Spinal muscular atrophy: an update on therapeutic progress. Biochim. Biophys. Acta 1832, 2180–2190 (2013).
  CAS PubMed Google Scholar
• Harahap, I. S. et al. Valproic acid increases SMN2 expression and modulates SF2/ASF and hnRNPA1 expression in SMA fibroblast cell lines. Brain Dev. 34, 213–222 (2012).
  PubMed Google Scholar
• Evans, M. C., Cherry, J. J. & Androphy, E. J. Differential regulation of the SMN2 gene by individual HDAC proteins. Biochem. Biophys. Res. Commun. 414, 25–30 (2011).
  CAS PubMed PubMed Central Google Scholar
• Kwon, D. Y., Motley, W. W., Fischbeck, K. H. & Burnett, B. G. Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. Hum. Mol. Genet. 20, 3667–3677 (2011).
  CAS PubMed PubMed Central Google Scholar
• Akimova, T., Beier, U. H., Liu, Y., Wang, L. & Hancock, W. W. Histone/protein deacetylases and T-cell immune responses. Blood 119, 2443–2451 (2012).
  CAS PubMed PubMed Central Google Scholar
• Halili, M. A., Andrews, M. R., Sweet, M. J. & Fairlie, D. P. Histone deacetylase inhibitors in inflammatory disease. Curr. Top. Med. Chem. 9, 309–319 (2009).
  CAS PubMed Google Scholar
• Hsieh, I. N. et al. Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009. Cell Death Dis. 5, e1166 (2014).
  CAS PubMed PubMed Central Google Scholar
• Joosten, L. A., Leoni, F., Meghji, S. & Mascagni, P. Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. Mol. Med. 17, 391–396 (2011).
  CAS PubMed PubMed Central Google Scholar
• Archin, N. M. et al. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 23, 1799–1806 (2009).
  CAS PubMed Google Scholar
• Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485 (2012). This is an important demonstration that HDAC inhibitors can affect viral latency.
  CAS PubMed PubMed Central Google Scholar
• Ritchie, D. et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica 94, 1618–1622 (2009).
  CAS PubMed PubMed Central Google Scholar
• Scala, S. et al. P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol. Pharmacol. 51, 1024–1033 (1997).
  CAS PubMed Google Scholar
• Xiao, J. J. et al. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J. Pharmacol. Exp. Ther. 313, 268–276 (2005).
  CAS PubMed Google Scholar
• Ruefli, A. A. et al. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int. J. Cancer 99, 292–298 (2002).
  CAS PubMed Google Scholar
• Lindemann, R. K. et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc. Natl Acad. Sci. USA 104, 8071–8076 (2007).
  CAS PubMed PubMed Central Google Scholar
• Newbold, A. et al. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol. Cancer Ther. 7, 1066–1079 (2008).
  CAS PubMed Google Scholar
• Fantin, V. R. et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 68, 3785–3794 (2008).
  CAS PubMed Google Scholar
• Fotheringham, S. et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15, 57–66 (2009). References 198 and 199 provide the first evidence for predictive biomarkers of tumour cell sensitivity to HDAC inhibitors.
  CAS PubMed Google Scholar
• Khan, O. et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc. Natl Acad. Sci. USA 107, 6532–6537 (2010).
  CAS PubMed PubMed Central Google Scholar
• Yeo, W. et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J. Clin. Oncol. 30, 3361–3367 (2012).
  CAS PubMed PubMed Central Google Scholar
• Chen, L., Shinde, U., Ortolan, T. G. & Madura, K. Ubiquitin-associated (UBA) domains in Rad23 bind ubiquitin and promote inhibition of multi-ubiquitin chain assembly. EMBO Rep. 2, 933–938 (2001).
  CAS PubMed PubMed Central Google Scholar
• Chen, L. & Madura, K. Rad23 promotes the targeting of proteolytic substrates to the proteasome. Mol. Cell. Biol. 22, 4902–4913 (2002).
  CAS PubMed PubMed Central Google Scholar
• New, M. et al. A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors. Cell Death Differ. 20, 1306–1316 (2013).
  CAS PubMed PubMed Central Google Scholar
• Xu, W., Ngo, L., Perez, G., Dokmanovic, M. & Marks, P. A. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc. Natl Acad. Sci. USA 103, 15540–15545 (2006).
  CAS PubMed PubMed Central Google Scholar
• Garcia-Manero, G. et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111, 1060–1066 (2008).
  CAS PubMed Google Scholar
• Hu, Y. et al. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate. Blood 116, 2732–2741 (2010).
  CAS PubMed PubMed Central Google Scholar
• Hug, B. A. & Lazar, M. A. ETO interacting proteins. Oncogene 23, 4270–4274 (2004).
  CAS PubMed Google Scholar
• Liu, S. et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res. 65, 1277–1284 (2005).
  CAS PubMed Google Scholar
• Shia, W. J. et al. PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. Blood 119, 4953–4962 (2012).
  CAS PubMed PubMed Central Google Scholar
• Roudaia, L. et al. CBFβ is critical for AML1-ETO and TEL-AML1 activity. Blood 113, 3070–3079 (2009).
  CAS PubMed PubMed Central Google Scholar
• Rice, K. L. & de The, H. The acute promyelotic leukemia (APL) success story: curing leukemia through targeted therapies. J. Intern. Med. 276, 61–70 (2014).
  CAS PubMed Google Scholar
• Villa, R. et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11, 513–525 (2007).
  CAS PubMed Google Scholar
• Gupta, P., Reid, R. C., Iyer, A., Sweet, M. J. & Fairlie, D. P. Towards isozyme-selective HDAC inhibitors for interrogating disease. Curr. Top. Med. Chem. 12, 1479–1499 (2012).
  CAS PubMed Google Scholar
• Salisbury, C. M. & Cravatt, B. F. Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc. Natl Acad. Sci. USA 104, 1171–1176 (2007).
  CAS PubMed PubMed Central Google Scholar
• Tessier, P. et al. Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 19, 5684–5688 (2009).
  CAS PubMed Google Scholar
• Malvaez, M. et al. HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc. Natl Acad. Sci. USA 110, 2647–2652 (2013).
  CAS PubMed PubMed Central Google Scholar
• Jochems, J. et al. Antidepressant-like properties of novel HDAC6 Selective inhibitors with improved brain bioavailability. Neuropsychopharmacology 39, 389–400 (2013).
  PubMed PubMed Central Google Scholar
• Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M. & Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl Acad. Sci. USA 100, 4389–4394 (2003).
  CAS PubMed PubMed Central Google Scholar
• Namdar, M., Perez, G., Ngo, L. & Marks, P. A. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc. Natl Acad. Sci. USA 107, 20003–20008 (2010).
  CAS PubMed PubMed Central Google Scholar
• Vishwakarma, S. et al. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects. Int. Immunopharmacol. 16, 72–78 (2013).
  CAS PubMed Google Scholar
• Kaliszczak, M. et al. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth. Br. J. Cancer 108, 342–350 (2013).
  CAS PubMed PubMed Central Google Scholar
• Lee, J. H. et al. Development of a histone deacetylase 6 inhibitor and its biological effects. Proc. Natl Acad. Sci. USA 110, 15704–15709 (2013).
  CAS PubMed PubMed Central Google Scholar
• Yu, C. W., Chang, P. T., Hsin, L. W. & Chern, J. W. Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease. J. Med. Chem. 56, 6775–6791 (2013).
  CAS PubMed Google Scholar
• Balasubramanian, S. et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22, 1026–1034 (2008).
  CAS PubMed Google Scholar
• Suzuki, T. et al. Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries. J. Med. Chem. 55, 9562–9575 (2012).
  CAS PubMed Google Scholar
• Saha, A. et al. Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity. Bioorg. Med. Chem. 21, 4201–4209 (2013).
  CAS PubMed Google Scholar
• Olson, D. E. et al. Discovery of the first histone deacetylase 6/8 dual inhibitors. J. Med. Chem. 56, 4816–4820 (2013).
  CAS PubMed Google Scholar
• Ruefli, A. A. et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl Acad. Sci. USA 98, 10833–10838 (2001).
  CAS PubMed PubMed Central Google Scholar
• Rosato, R. R., Almenara, J. A. & Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 63, 3637–3645 (2003).
  CAS PubMed Google Scholar
• Butler, L. M. et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl Acad. Sci. USA 99, 11700–11705 (2002).
  CAS PubMed PubMed Central Google Scholar
• Robert, C. & Rassool, F. V. HDAC inhibitors: roles of DNA damage and repair. Adv. Cancer Res. 116, 87–129 (2012).
  CAS PubMed Google Scholar
• Kachhap, S. K. et al. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS ONE 5, e11208 (2010).
  PubMed PubMed Central Google Scholar
• Petruccelli, L. A. et al. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS ONE 6, e20987 (2011).
  CAS PubMed PubMed Central Google Scholar
• Conti, C. et al. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res. 70, 4470–4480 (2010).
  CAS PubMed PubMed Central Google Scholar
• Dai, Y., Rahmani, M., Dent, P. & Grant, S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol. Cell. Biol. 25, 5429–5444 (2005).
  CAS PubMed PubMed Central Google Scholar
• Chen, C. S. et al. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res. 67, 5318–5327 (2007).
  CAS PubMed Google Scholar
• Newbold, A., Salmon, J., Stanley, K. & Johnstone, R. The role of p21waf1/cip1 and p27Kip1 in HDACi-mediated tumor cell death and cell cycle arrest. Oncogene http://dx.doi.org/10.1038/onc.2013.482 (2013).
• Lindemann, R. K., Gabrielli, B. & Johnstone, R. W. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3, 779–788 (2004).
  CAS PubMed Google Scholar
• Gabrielli, B. & Brown, M. Histone deacetylase inhibitors disrupt the mitotic spindle assembly checkpoint by targeting histone and nonhistone proteins. Adv. Cancer Res. 116, 1–37 (2012).
  CAS PubMed Google Scholar
• Qiu, L. et al. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell 11, 2069–2083 (2000).
  CAS PubMed PubMed Central Google Scholar
• Munro, J., Barr, N. I., Ireland, H., Morrison, V. & Parkinson, E. K. Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. Exp. Cell Res. 295, 525–538 (2004).
  CAS PubMed Google Scholar
• Rebbaa, A., Zheng, X., Chu, F. & Mirkin, B. L. The role of histone acetylation versus DNA damage in drug-induced senescence and apoptosis. Cell Death Differ. 13, 1960–1967 (2006).
  CAS PubMed Google Scholar
• Place, R. F., Noonan, E. J. & Giardina, C. HDACs and the senescent phenotype of WI-38 cells. BMC Cell Biol. 6, 37 (2005).
  PubMed PubMed Central Google Scholar
• Terao, Y. et al. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int. J. Cancer 94, 257–267 (2001).
  CAS PubMed Google Scholar
• Pazolli, E. et al. Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression. Cancer Res. 72, 2251–2261 (2012).
  CAS PubMed PubMed Central Google Scholar
• Ablain, J. & de The, H. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 117, 5795–5802 (2011).
  CAS PubMed Google Scholar
• Gottlicher, M. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969–6978 (2001).
  CAS PubMed PubMed Central Google Scholar
• Leiva, M. et al. Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia 26, 1630–1637 (2012).
  CAS PubMed Google Scholar
• Lin, R. J. et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391, 811–814 (1998).
  CAS PubMed Google Scholar
• Fredly, H. et al. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clin. Epigenet. 5, 13 (2013).
  Google Scholar
• Cimino, G. et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res. 66, 8903–8911 (2006).
  CAS PubMed Google Scholar
• Lee, Y. J. et al. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Int. J. Med. Sci. 9, 881–893 (2012).
  CAS PubMed PubMed Central Google Scholar
• Robert, T. et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 471, 74–79 (2011).
  CAS PubMed PubMed Central Google Scholar
• Shao, Y., Gao, Z., Marks, P. A. & Jiang, X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 101, 18030–18035 (2004).
  CAS PubMed PubMed Central Google Scholar
• Liu, Y. L. et al. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy 6, 1057–1065 (2010).
  CAS PubMed Google Scholar
• Gammoh, N. et al. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc. Natl Acad. Sci. USA 109, 6561–6565 (2012).
  CAS PubMed PubMed Central Google Scholar
• Dupere-Richer, D. et al. Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance. Cell Death Dis. 4, e486 (2013).
  CAS PubMed PubMed Central Google Scholar
• Song, W. et al. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 25, 161–168 (2011).
  CAS PubMed Google Scholar
• Ning, Z. Q. et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother. Pharmacol. 69, 901–909 (2012).
  CAS PubMed Google Scholar
• Murakami, T. et al. Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J. Invest. Dermatol. 128, 1506–1516 (2008).
  CAS PubMed Google Scholar
• Northrop, J. K., Wells, A. D. & Shen, H. Cutting edge: chromatin remodeling as a molecular basis for the enhanced functionality of memory CD8 T cells. J. Immunol. 181, 865–868 (2008).
  CAS PubMed Google Scholar
• Fann, M. et al. Histone acetylation is associated with differential gene expression in the rapid and robust memory CD8+ T-cell response. Blood 108, 3363–3370 (2006).
  CAS PubMed PubMed Central Google Scholar
• Shen, L. et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS ONE 7, e30815 (2012).
  CAS PubMed PubMed Central Google Scholar
• Bridle, B. W. et al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol. Ther. 21, 887–894 (2013).
  CAS PubMed PubMed Central Google Scholar
• Shen, L. & Pili, R. Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. Oncoimmunology 1, 948–950 (2012).
  PubMed PubMed Central Google Scholar
• Villagra, A., Sotomayor, E. M. & Seto, E. Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene 29, 157–173 (2010).
  CAS PubMed Google Scholar
• Cantley, M. D. & Haynes, D. R. Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs. Inflammopharmacology 21, 301–307 (2013).
  CAS PubMed Google Scholar
• Schmudde, M., Friebe, E., Sonnemann, J., Beck, J. F. & Broker, B. M. Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions. Cancer Lett. 295, 173–181 (2010).
  CAS PubMed Google Scholar
• Reddy, P. et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl Acad. Sci. USA 101, 3921–3926 (2004).
  CAS PubMed PubMed Central Google Scholar
• Reddy, P. et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118, 2562–2573 (2008). This study provides preclinical evidence that HDAC inhibitors may be effective in immune-based disorders.
  CAS PubMed PubMed Central Google Scholar
• Kwon, H. J., Kim, M. S., Kim, M. J., Nakajima, H. & Kim, K. W. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer 97, 290–296 (2002).
  CAS PubMed Google Scholar
• Williams, R. J. Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin. Investig. Drugs 10, 1571–1573 (2001).
  CAS PubMed Google Scholar
• Deroanne, C. F. et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21, 427–436 (2002).
  CAS PubMed Google Scholar
• Ellis, L., Hammers, H. & Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 280, 145–153 (2009).
  CAS PubMed Google Scholar
• Ryu, H. et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl Acad. Sci. USA 100, 4281–4286 (2003).
  CAS PubMed PubMed Central Google Scholar
• Langley, B. et al. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J. Neurosci. 28, 163–176 (2008).
  CAS PubMed PubMed Central Google Scholar
• Leng, Y. & Chuang, D. M. Endogenous α-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci. 26, 7502–7512 (2006).
  CAS PubMed PubMed Central Google Scholar
• Saunders, K. O., Freel, S. A., Overman, R. G., Cunningham, C. K. & Tomaras, G. D. Epigenetic regulation of CD8+ T-lymphocyte mediated suppression of HIV-1 replication. Virology 405, 234–242 (2010).
  CAS PubMed Google Scholar